ClinConnect ClinConnect Logo
Search / Trial NCT00594464

A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery

Launched by UCB PHARMA · Jan 3, 2008

Trial Information

Current as of July 22, 2025

Completed

Keywords

Rotigotine Neupro® Parkinson's Disease (Pd) Perioperative Use Anaesthesia,

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject has idiopathic Parkinson's disease (early- or advanced-stage), as defined by the cardinal sign bradykinesia, plus the presence of at least one of the following: resting tremor, rigidity, or postural instability and is without any other known or suspected cause of Parkinsonism.
  • Subject is scheduled for an operation requiring general anesthesia.
  • Exclusion Criteria:
  • Subject has previously been treated with rotigotine.
  • Subject has a history of significant skin hypersensitivity to adhesives or other transdermals or recent unresolved contact dermatitis or has a known allergy or hypersensitivity to rotigotine or to other components of the patch.
  • Subject is scheduled for a surgical procedure (surgery per protocol(SPP)) that requires magnetic resonance imaging or cardioversion.
  • Subject has a high probability to require extended postoperative ventilation (\> 24 hours).
  • Subject has any medical condition that, in the opinion of the investigator, could jeopardize or compromise the subject's ability to participate in this trial.

About Ucb Pharma

UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.

Locations

Augsburg, , Germany

Ulm, , Germany

Bremerhaven, , Germany

Dresden, , Germany

Bonn, , Germany

Kiel, , Germany

Bochum, , Germany

Stralsund, , Germany

Dortmund, , Germany

Schwerin, , Germany

Hanau, , Germany

Ingolstadt, , Germany

Patients applied

0 patients applied

Trial Officials

UCB Clinical Trial Call Center

Study Director

+1 877 822 9493 (UCB)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials